WEUSKOP5410: Observational Study in ENABLE Clinical Trials


Phase N/A Results N/A

Summary of Purpose

Hepatitis C Virus (HCV) is a leading cause of chronic liver disease (CLD) worldwide. Current mainstay of treatment is combination therapy with pegylated interferon and ribavarin. Thrombocytopenia as a treatment related adverse event or a complication of chronic liver disease often necessitates dose reduction and discontinuation in these patients. Revolade®/Promacta® (eltrombopag) is an oral second generation...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 5 December 2013.

1 May 2011 7 Jul 2011 1 Nov 2013 1 Nov 2013 1 Dec 2013 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics


Conditions See All


Trial Design

  • Observation: Case Control
  • Perspective: Retrospective
  • Sampling: Non-Probability Sample


Not available